Key result
Combination therapy with ACE inhibitors and spironolactone or aliskiren reduced mortality compared to ACE inhibitors alone.
Why the study?
Does the addition of spironolactone, valsartan, or aliskiren to ACE inhibitors reduce mortality and improve right heart function in patients with severe systolic chronic heart failure?
RCT (n=148)
Randomized into 4 groups
Does the addition of spironolactone, valsartan, or aliskiren to ACE inhibitors reduce mortality and improve right heart function in patients with severe systolic chronic heart failure?
Adding spironolactone or aliskiren to ACE inhibitors significantly reduces mortality and improves right heart function and biomarkers in patients with severe systolic heart failure compared to ACE inhibitors alone.
Answers are grounded in this paper and cite their sources.
Supports dual RAAS blockade in severe systolic HF; confirms mortality benefit and right heart gains in RCT.
Aim. To compare the effects of renin-angiotensin-aldosterone system (RAAS) modulators in patients with severe chronic heart failure (CHF). Material and methods. In total, 148 patients (57,4±0,4 years), with severe systolic left ventricular (LV) dysfunction (ejection fraction (EF) <40%) were randomized into 4 groups: Group A (n=38), receiving only ACE inhibitors; Group B (n=37), receiving spironolactone (up to 50 mg); Group C (n=37), receiving valsartan (up to 320 mg); and Group D (n=36), receiving aliskiren (up to 300 mg), in addition to ACE inhibitors, diuretics, b -adrenoblockers, and digoxin. The follow-up phase was 37±0,7 months. Results. There was a significant reduction in one-year mortality (relative risk (RR) reduction by 31,6% and 47,2%), two-year mortality (RR reduction by 38,6% and 50%), and three-year mortality (RR reduction 32% and 40,1%) in patients receiving ACE inhibitors in combination with spironolactone (p<0,05) or aliskiren (p<0,01), compared to Group A. Right heart functional parameters, as well as the levels of brain natriuretic peptide (BNP) and C-reactive protein (CRP) significantly improved after 12 months in Group A, compared to 6 months in Groups B and C, and to 3 months in Group D. Conclusion. The combination therapy with ACE inhibitors and spironolactone or aliskiren significantly reduced the risk of mortality and hospitalisation, while the combination therapy with valsartan was associated only with reduced hospitalisation risk. Aliskiren therapy was linked to a significant improvement in right heart function, BNP and CRP levels, and a reduced risk of mortality and hospitalisation.
No takes yet. Share an insight, caveat, or question.
Adamyan et al. (2012) conducted an RCT in Severe chronic heart failure (n=148). Spironolactone, valsartan, or aliskiren added to standard therapy vs. ACE inhibitors alone (with standard therapy) was evaluated on Mortality (one-year, two-year, and three-year) (RR reduction 31.6% to 50%, p=<0.05). Combination therapy with ACE inhibitors and spironolactone or aliskiren reduced mortality compared to ACE inhibitors alone.
Synapse has enriched 10 related papers. Consider them for comparative context: